Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asherie

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Journal of Molecular Biology|December 6, 2001
Enhanced crystallization of the Cys18 to Ser mutant of bovine gammaB crystallinN Asherie, J Pande, A Pande, et al.
Haematologica|March 31, 2022
Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myelomaOrtal Harush, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.
Acta Crystallographica. Section D, Biological Crystallography|March 12, 2015
Crystallization of lysozyme with (R)-, (S)- and (RS)-2-methyl-2,4-pentanediolMark Stauber, Jean Jakoncic, Jacob Berger, et al.
British Journal of Haematology|April 18, 2023
Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphomaT Dubnikov Sharon, M Assayag, B Avni, et al.
Plos One|December 2, 2015
Can CD44 Be a Mediator of Cell Destruction? The Challenge of Type 1 DiabetesNathalie Assayag-Asherie, Dror Sever, Marika Bogdani, et al.
Cancers|November 13, 2025
High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T)Ariela Arad, Maya Katz, Eyal Lebel, et al.
Haematologica|October 6, 2022
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trialNathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, et al.
Cancers|July 14, 2023
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?Vladimir Vainstein, Batia Avni, Sigal Grisariu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2022
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL AmyloidosisShlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, et al.
Annals of the New York Academy of Sciences|October 4, 2007
CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout miceDavid Naor, Shlomo Nedvetzki, Marita Walmsley, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Journal of Molecular Biology|December 6, 2001
Enhanced crystallization of the Cys18 to Ser mutant of bovine gammaB crystallinN Asherie, J Pande, A Pande, et al.
Haematologica|March 31, 2022
Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myelomaOrtal Harush, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.
Acta Crystallographica. Section D, Biological Crystallography|March 12, 2015
Crystallization of lysozyme with (R)-, (S)- and (RS)-2-methyl-2,4-pentanediolMark Stauber, Jean Jakoncic, Jacob Berger, et al.
British Journal of Haematology|April 18, 2023
Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphomaT Dubnikov Sharon, M Assayag, B Avni, et al.
Plos One|December 2, 2015
Can CD44 Be a Mediator of Cell Destruction? The Challenge of Type 1 DiabetesNathalie Assayag-Asherie, Dror Sever, Marika Bogdani, et al.
Cancers|November 13, 2025
High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T)Ariela Arad, Maya Katz, Eyal Lebel, et al.
Haematologica|October 6, 2022
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trialNathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, et al.
Cancers|July 14, 2023
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?Vladimir Vainstein, Batia Avni, Sigal Grisariu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2022
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL AmyloidosisShlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, et al.
Annals of the New York Academy of Sciences|October 4, 2007
CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout miceDavid Naor, Shlomo Nedvetzki, Marita Walmsley, et al.
Pageof 4